SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, has introduced a new product line of high medical value biomarkers for response, resistance and pathway interrogation called PRECIS Precision Medicine by bioTheranostics(SM). Precision medicine, a new paradigm in cancer management, partners accurate diagnosis of primary tumor site and predictive biomarkers to drive targeted therapy. The PRECIS tests help oncologists predict potential response and evaluate underlying disease pathways as they consider targeted therapies.
The PRECIS product line includes biomarker profiles for non-small cell lung cancer and colorectal cancer and detects clinically relevant tumor biomarkers EGFR, ALK rearrangement, KRAS, BRAF, c-MET, PIK3CA and 10q23 deletion to aid in characterizing disease behavior and therapeutic effectiveness.
"An unmet need for targeted therapy treatments in metastatic cancer is accurate tumor classification plus knowledge of the activated signal transduction pathway driving cancer growth," said Richard Ding, Chief Executive Officer of bioTheranostics. "The use of CancerTYPE ID®, the leading molecular classifier to aid physicians in ascertaining tumor origin, and PRECIS Precision Medicine biomarkers has significant potential to improve cancer diagnosis and help oncologists efficiently formulate an optimal personalized treatment plan.
"The launch of PRECIS is a key milestone for bioTheranostics as the company moves to become an integrated diagnostic solution provider in cancer management," said Ding. "The PRECIS test menu provides cutting-edge tumor pathway information on therapeutic prediction and resistance mechanisms.
"We will continue to expand our testing menu as more predictive biomarkers demonstrate their clinical utility. Our physician customers have also indicated that the turn
|SOURCE bioTheranostics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved